Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.50 |
| ▸ | CNR1 | P21554 | 5/20 | 0.50 |
| ▸ | CNR2 | P34972 | 5/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23793654 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL9403437 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL4408312 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL8906309 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL21236012 | 0.98 | GNAI3 (0.50) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL23793834 | 0.94 | GNAI3 (0.44) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL316348 | 0.92 | SMN1; SMN2 (0.48) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL10495774 | 0.90 | HMGCR (0.50) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL9403390 | 0.88 | GNAI3 (0.52) | GNAI3GNAO1GNAI1TRPV1CNR1 | |
| SCHEMBL10719860 | 0.88 | GNAI3 (0.52) | GNAI3GNAO1GNAI1TRPV1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134009-B2 | Process for the oxidation of secondary amines into the corresponding nitroxides | BASF SE (DE) | 2012-03-13 | — | — | US | disclosed |
| US-20100305322-A1 | Process for the Oxidation of Secondary Amines into the Corresponding Nitroxides | CIBA SPECIALTY CHEMICALS CORPORATION | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305322-A1 | Process for the Oxidation of Secondary Amines into the Corresponding Nitroxides | NOS2, NOS1, NOS3 | GNAI3 2968/4885GNAO1 686/4885GNAI1 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.